Kirn David has filed 17 insider transactions across 1 company since December 2023.
Most recent transaction: a grant/award of 750000 shares of 4D Molecular Therapeutics, Inc. ($FDMT) on March 25, 2026.
Activity breakdown: 0 open-market purchases and 9 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 25, 2026 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | A | Stock Option (Right to Buy) | 750000 | $0.00 | 750,000.0000 | 57,135,075 | 9999.99% | 1.31% |
| March 6, 2025 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | A | Stock Option (Right to Buy) | 267500 | $0.00 | 267,500.0000 | 46,302,407 | 9999.99% | 0.58% |
| July 10, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | M | Common Stock | 1270 | $15.78 | 1,072,076.0000 | 0 | 0.12% | 0.00% |
| July 10, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 12923 | $22.49 | 1,059,153.0000 | 0 | 1.21% | 0.00% |
| July 10, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | M | Stock Option (Right To Buy) | 11653 | $0.00 | 565,417.0000 | 0 | 2.02% | 0.00% |
| July 10, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | M | Stock Option (Right To Buy) | 1270 | $0.00 | 148,730.0000 | 0 | 0.85% | 0.00% |
| July 10, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | M | Common Stock | 11653 | $14.42 | 1,070,806.0000 | 0 | 1.10% | 0.00% |
| June 24, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 12930 | $23.10 | 1,059,153.0000 | 0 | 1.21% | 0.00% |
| June 24, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | M | Stock Option (Right To Buy) | 12930 | $0.00 | 577,070.0000 | 0 | 2.19% | 0.00% |
| June 24, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | M | Common Stock | 12930 | $14.42 | 1,072,083.0000 | 0 | 1.22% | 0.00% |
| Feb. 8, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 92001 | $27.13 | 1,059,153.0000 | 0 | 7.99% | 0.00% |
| Jan. 23, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 5696 | $18.41 | 1,151,154.0000 | 0 | 0.49% | 0.00% |
| Dec. 18, 2023 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 4702 | $18.13 | 1,225,819.0000 | 0 | 0.38% | 0.00% |
| Jan. 5, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 28104 | $19.56 | 1,156,983.0000 | 0 | 2.37% | 0.00% |
| Jan. 5, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 133 | $20.11 | 1,156,850.0000 | 0 | 0.01% | 0.00% |
| Jan. 4, 2024 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 40732 | $20.31 | 1,185,087.0000 | 0 | 3.32% | 0.00% |
| Dec. 15, 2023 | 4D Molecular Therapeutics, Inc. | $FDMT | Kirn David | Chief Executive Officer | S | Common Stock | 28632 | $17.27 | 1,230,521.0000 | 0 | 2.27% | 0.00% |